Apyx Medical (NASDAQ:APYX – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01, Zacks reports. The firm had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $11.66 million. Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. During the same period in the previous year, the business earned ($0.13) earnings per share. Apyx Medical updated its FY 2025 guidance to EPS and its FY 2024 guidance to EPS.
Apyx Medical Trading Down 2.6 %
Shares of NASDAQ APYX traded down $0.04 during mid-day trading on Monday, reaching $1.48. 115,723 shares of the company’s stock were exchanged, compared to its average volume of 34,076. The firm has a market capitalization of $51.27 million, a price-to-earnings ratio of -1.78 and a beta of 1.21. The company has a debt-to-equity ratio of 2.26, a quick ratio of 4.45 and a current ratio of 5.33. Apyx Medical has a 52-week low of $0.97 and a 52-week high of $3.26. The company’s 50-day moving average is $1.21 and its 200-day moving average is $1.33.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on APYX shares. Craig Hallum upgraded Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. BTIG Research started coverage on Apyx Medical in a report on Thursday, October 17th. They issued a “neutral” rating for the company. Finally, JMP Securities restated a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th.
About Apyx Medical
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.
Recommended Stories
- Five stocks we like better than Apyx Medical
- The How and Why of Investing in Gold Stocks
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- The Basics of Support and Resistance
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- What is the Australian Securities Exchange (ASX)
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.